top of page

CELL-DERIVED
XENOGRAFT 

MODELS

DOMESTIC QUALITY at COMPETITIVE PRICES

 

When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA, at competitive prices

SPEED TO INITIATION
 

Most efficacy studies can be initiated within two business days.

PERSONAL TOUCH

 

We love our clients!  We are flexible and easy to work with.  And we take a personal interest in our clients' studies. 

Cell-Derived Xenografts entail the implantation of human cancer cells into a host animal, typically an immunocompromised mouse or rat.  Xenograft models are effective tools for assessing in vivo efficacy of candidate cancer drugs.   
 
Other options include:
  • Custom xenograft study designs
  • Fluorescent imaging
  • MTD studies
  • Pre-clinical drug formulation
  • Tumor collection, organ collection, histology
  • Pharmacodynamic studies (e.g. ELISA, Luminex, PCR, sequencing, flow cytometry)

 Please see below for our available models or to request a quote

XENOGRAFT 
cell lines 

Filter items by Organ
Cell line
Organ
Mutations
Weeks from stratification to termination (average)
Growth Curve
22Rv1
Prostate
KMT2D, PIK3CA, TP53
5
786-0
Renal
PTEN, TERT, TP53, VHL
N/A
A-375
Skin
BRAF, CDKN2A, TERT
4
A431
Skin
TP53, EGFR-PPARGC1A fussion
N/A
A498
Renal
PIK3CB, VHL
5
A549
Lung
KRAS, STK11, TP53
6
A673
Sarcoma
BRAF, TP53, EWS-FLI1 fusion
3
AGS
Gastric
CTNNB1, KRAS, PIK3CA, TP53
6
BxPc-3
Pancreatic
BRAF, KRAS, TP53
7
CHLA-06
Brain
TP53
6
Caki-1
Renal
RB1
4
Colo-205
Colon
APC, BRAF, CTNNB1, TP53
2.5
DLD-1
Colon
APC, ACVR2A, B2M, EP300, KRAS, PIK3CA, TGFBR2, TP53
4
DU-145
Prostate
CDKN2A, RB1, STK11, TP53
6
ES-2-luc
Ovarian
BRAF, PALB2, TERT, TP53
3.5
HCC1954
Breast
PIK3CA, TP53, CLTC-VMP1 fusion
7
HCT-116
Colon
ACVR2A, BRCA2, CDKN2A, CTNNB1, EP300, KRAS, PIK3CA, PPM1D, TGFBR2, TP53
5
HT-29
Colon
APC, BRAF, PIK3CA, SMAD4, TP53
N/A
HuCCT1
Bile Duct
KRAS, MSH6, TP53
5
Huh-7
Liver
KDR, POLD3, TERT, TP53
4
JIMT-1
Breast
PIK3CA, TP53
8
JeKo-1
Blood
TP53
5
LASCPC-01
Prostate
Unavailable
3
LNCaP
Prostate
AR, MEN1, PIK3R1, PTEN, TP53
4
MDA-MB-231
Breast
CDKN2A, CDKN2B, BRAF, KRAS, TERT, TP53
4
MDA-MB-468
Breast
PTEN, RB1, TP53
N/A
MIAPaCa-2
Pancreatic
KRAS, TP53
8
MOLM-13
Blood
FLT3, KMT2A-MLLT3 fusion
14
NCI-H1703
Lung
CDKN2A, TP53
3
NCI-H1975
Lung
EGFR, PIK3CA, TP53
6
NCI-H460
Lung
KRAS, PIK3CA, STK11, TP53
5
NCI-N87
Gastric
ERBB3, TP53
6
OCI-AML-3
Blood
DNMT3A, NRAS, NPM1
2
OCI-Ly1
Blood
Unavailable
N/A
OVCAR8
Ovarian
CTNNB1, ERBB2, KRAS, TP53
8
PANC-1
Pancreatic
KRAS, TP53
3
PC-3
Prostate
TP53
4
SK-BR-3
Breast
TP53
4
SK-N-FI
Brain
NF1, TP53
4
SK-N-MC
Sarcoma
TP53, EWS-FLI1 fusion
3
SK-OV-3
Ovarian
APC, FBXW7, PIK3CA, TP53
10
SKM-1
Blood
ASXL1, BCORL1, EZH2, KRAS, TP53
3
SU-DHL-16
Blood
Unavailable
4
SW480
Colon
APC, KRAS, TP53
4
TT
Thyroid
RET, TBX3
4
U-87MG
Brain
Unavailable
3
U118-MG
Brain
IDH1, PTEN, TP53
6
UM-UC-3
Bladder
KRAS, PARD3B, TERT, TP53
N/A
VcAP
Prostate
MLH1, TP53, TMPRss2-ERG fusion
N/A
WITT (SK-Cha-1)
Bile Duct
Unavailable
N/A
WM164
Skin
BRAF
6
YAPC
Pancreatic
KRAS, TP53
N/A

*Other cell lines are possible, please contact us about your cell line of choice

IMG_5352.jpg

QUOTE REQUEST FORM
cell-derived xenograft models

Please fill out the form below

We will respond with a quote within one business day

Route of Administration?
Other options:
Is the planned study part of a grant application?

MEET OUR SCIENTIFIC DIRECTOR

Bret Stephens, PhD
  • LinkedIn Social Icon

Dr. Stephens has a broad in vivo biology background that comes from twenty years of involvement in cancer drug discovery in both academic and pharmaceutical industry settings.

 

Dr. Stephens received his PhD in Molecular Biology from the University of Arizona.

 

Previous to joining Rincon Bio, Dr. Stephens worked at Tolero Pharmaceuticals, Huntsman Cancer Institute (University of Utah), and the BioDesign Institute (Arizona State University), where he focused on cancer small molecule drug development.

ABOUT US

Founded in 2013, Rincon Bio is a pre-clinical CRO focusing on in vivo cancer efficacy studies, both allogeneic (human cell models) and syngeneic (immunotherapy models).

 

The staff at Rincon Bio have performed hundreds of efficacy studies for pharmaceutical researchers across the United States and Europe, both in industry and in academia. We've worked in the world of small, agile, start-up pharma, which gives us a unique perspective as a CRO.  We appreciate that your priorities change quickly, and you need a partner that can adapt along with you.  Furthermore, we can initiate most efficacy studies more quickly than any other CRO. 

 

We understand the importance of transparency and communication: at Rincon Bio, our clients are assigned a single point-of-contact, who is responsible for managing their study from conception to completion. 

Rincon Bio is a US-based organization, born from a desire to simplify the process of running cancer efficacy studies, and to provide domestic quality at competitive prices. We are The Cancer Model CRO - we believe in doing one thing, and doing it well.  

 

If you do decide to run your study at Rincon Bio, the process will be easy, streamlined, and pleasant.  

 

Email: info@rinconbio.com
Tel:  760-713-6613

Utah: 

3900 N Traverse Mountain Blvd

Suite 100

Lehi, UT 84043

California: 

3156 Vista Way, Suite 220

Oceanside, CA 92056

 

CONTACT US
bottom of page